ABVC BioPharma Inc
ABVC BioPharma Inc (ABVC) Covered Calls
ABVC BioPharma Inc trades in the Biotechnology industry with an IV Rank of 44.84%, average versus the past year. ABVC's highest covered call setup is the $2.50 strike expiring May 21, 2027, sorted by theoretical annualized return. It's 174.73% out of the money with 189 days to expiration, a 180.22% return until expiration, and a 348.04% theoretical annualized return. Across the setups shown, annualized returns run from 348.04% to 348.04% at strikes between $2.50 and $2.50, with 189 to 189 days to expiration, as of Nov 13, 2026.
Read more
Running ABVC covered calls helps you generate income from ABVC BioPharma Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best ABVC covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If ABVC stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling ABVC covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given ABVC covered call is worth writing.
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.
| 2027-05-21 | 189 | 2.50 | 174.73 | 0.05 | 5.00 | 164.00 | 180.22 | 348.04 | -5.49 | +1.00 | 1 | 4.95 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank44.84% Moderate
- Market cap (M$)25
- 52 weeks high-69.28%
- 52 weeks low32.39%
- Analyst recommendation—
- Target price—
- Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-0.16
- EPS growth next 5 years—
As of Nov 13, 2026